Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
Jin Hee Shin,1 Kishore M Gadde2 1Department of Community and Family Medicine, Duke University Medical Center, 2Obesity Clinical Trials Program, Duke University Medical Center, Durham, NC, USA Abstract: Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-re...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8e7b8c78bbcb44519fdfc944b618afb1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8e7b8c78bbcb44519fdfc944b618afb1 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8e7b8c78bbcb44519fdfc944b618afb12021-12-02T04:34:20ZClinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity1178-7007https://doaj.org/article/8e7b8c78bbcb44519fdfc944b618afb12013-04-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-of-phenterminetopiramate-qsymiatrade-combination-for--a12677https://doaj.org/toc/1178-7007Jin Hee Shin,1 Kishore M Gadde2 1Department of Community and Family Medicine, Duke University Medical Center, 2Obesity Clinical Trials Program, Duke University Medical Center, Durham, NC, USA Abstract: Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications – seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns. Keywords: Qsymia, combination drug, antiobesity drugs, phentermine, topiramate, obesity, weight lossShin JHGadde KMDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 131-139 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Specialties of internal medicine RC581-951 |
| spellingShingle |
Specialties of internal medicine RC581-951 Shin JH Gadde KM Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity |
| description |
Jin Hee Shin,1 Kishore M Gadde2 1Department of Community and Family Medicine, Duke University Medical Center, 2Obesity Clinical Trials Program, Duke University Medical Center, Durham, NC, USA Abstract: Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications – seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns. Keywords: Qsymia, combination drug, antiobesity drugs, phentermine, topiramate, obesity, weight loss |
| format |
article |
| author |
Shin JH Gadde KM |
| author_facet |
Shin JH Gadde KM |
| author_sort |
Shin JH |
| title |
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity |
| title_short |
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity |
| title_full |
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity |
| title_fullStr |
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity |
| title_full_unstemmed |
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity |
| title_sort |
clinical utility of phentermine/topiramate (qsymia™) combination for the treatment of obesity |
| publisher |
Dove Medical Press |
| publishDate |
2013 |
| url |
https://doaj.org/article/8e7b8c78bbcb44519fdfc944b618afb1 |
| work_keys_str_mv |
AT shinjh clinicalutilityofphenterminetopiramateqsymiatradecombinationforthetreatmentofobesity AT gaddekm clinicalutilityofphenterminetopiramateqsymiatradecombinationforthetreatmentofobesity |
| _version_ |
1718401135593652224 |